179 results about "Ribose" patented technology

The invention discloses temozolomide derivatives or pharmaceutically acceptable salts, crystal forms and solvates, wherein the structure of the temozolomide derivatives is shown as a formula I in the specification. According to the temozolomide derivative disclosed by the invention, damage caused by repairing temozolomide by cells is prevented by inhibiting PARP1 protein, so that the purpose of improving the overall anti-glioblastoma effect is achieved. The invention further discloses application of the temozolomide derivative or the pharmaceutically acceptable salt, the crystal form and the solvate to preparation of a PARP1 inhibitor. The invention also discloses application of the temozolomide derivative or the pharmaceutically acceptable salt, the crystal form and the solvate in preparation of medicines for preventing and / or treating tumors. The invention also discloses a pharmaceutical composition, and the pharmaceutical composition takes a safe and effective amount of temozolomide derivative or pharmaceutically acceptable salt, crystal form and solvate as effective components or main effective components, and is prepared into a pharmaceutically acceptable dosage form together with a pharmaceutically acceptable carrier.

The present invention provides a method for producing ribose-1-phosphate that is simple and yields improved efficiency. [Solution] A method for producing ribose-1-phosphate, comprising a contact step to produce ribose-1-phosphate and hypoxanthine by contacting inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium in a reaction solution containing inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium, wherein in the contact step, the hypoxanthine is present in an amount exceeding the saturation concentration relative to the medium.

The invention provides a method for cultivating anti-aging glutinous highland barley, highland barley starch as well as a preparation method and application of the highland barley starch, and particularly relates to a method for improving the starch quality character of an existing high-quality glutinous highland barley variety, in particular to a method for cultivating anti-aging glutinous highland barley by utilizing a gene editing technology without exogenous DNA (Deoxyribose Nucleic Acid) integration. A method for fixed-point knockout of an SSIIa gene to cultivate an anti-aging glutinous highland barley new strain under the background of a "Zhengnongglutinous 232" variety comprises the following steps: providing an acceptor material derived from a highland barley variety "Zhengnongglutinous 232" with a glutinous character, and deleting a Wx gene function of the "Zhengnongglutinous 232"; the method comprises the following steps: assembling guide RNA (Ribonucleic Acid) designed aiming at an SSIIa gene and Cas9 protein in vitro to form a ribonucleoprotein RNP complex; introducing the RNP complex into cells of an acceptor material so as to enable Cas9 protein to generate double-chain breakage at a target site of the SSIIa gene; carrying out culture and plant regeneration on the introduced cells to obtain a T0-generation plant of which the SSIIa gene is edited; and screening plants with the function loss of the SSIIa gene, wherein the plants keep the glutinous character of adult agricultural glutinous 232.

The invention relates to lipid nanoparticles for fish in-vivo skin gene editing and application of the lipid nanoparticles, and belongs to the technical field of fish gene editing. The lipid nanoparticle for fish in-vivo skin gene editing comprises a gene editing element and a lipid layer, wherein the lipid layer wraps the surface of the gene editing element; the gene editing element is a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas9 (CRISPR associated protein 9) ribonucleoprotein compound or nucleic acid for coding the compound; the lipid nanoparticle carrier comprises ionizable cationic lipid, auxiliary lipid, cholesterol, pegylated lipid and permanent cationic lipid, and the lipid nanoparticle carrier comprises the following components in parts by mole: 15 parts of ionizable cationic lipid, 25-30 parts of auxiliary lipid, 30 parts of cholesterol, 3 parts of pegylated lipid and 7 parts of permanent cationic lipid. The formula is high in pertinence, high in editing efficiency, simple, convenient and safe to operate and wide in application prospect.

The present disclosure provides compounds, in part, compounds having Formula (I) or Formula (II), and their use in the treatment of medical diseases or disorders, such as neurodegenerative diseases, e.g., Parkinson's disease. Pharmaceutical compositions and methods of making the compounds of the present disclosure are provided. These compounds are envisaged to be modulators, e.g., inhibitors, of cyclic ADP ribohydrolase (CD38).

The invention discloses a lysosome targeted degradation system based on a DNA phase separation aggregate as well as a preparation method and application of the lysosome targeted degradation system, and belongs to the technical field of biological medicine and nanotechnology. The lysosome targeted degradation system based on the DNA phase separation aggregate comprises an RNA-DNA tetrahedral framework with a cohesive end, the RNA-DNA tetrahedral framework is formed by self-assembly of a core chain and an edge chain through complementary base pairing, the edge chain is a DNA-RNA chimeric oligonucleotide chain, and the DNA-RNA chimeric oligonucleotide chain is a DNA-RNA chimeric oligonucleotide chain. One or more sections of RNA ribonucleotide sequences which can be specifically recognized and cut by RNase H enzyme are embedded in the sequence, and the tail end of the RNA ribonucleotide sequence is modified with a cohesive tail end for driving phase separation and a cell membrane anchoring group; the RNA-DNA tetrahedral framework is modified with an aptamer of a targeted membrane protein. After entering cells, the system is subjected to liquid-liquid phase separation in a lysosome acid environment through interaction of cohesive ends, a micron-sized large-size aggregate is formed in situ, the residence time of a nano-drug in the lysosome is prolonged, and efficient degradation of target membrane protein is realized.

This invention belongs to the field of antitumor drug technology, specifically relating to PARP inhibitor-quinoline carboxylic acid coupled derivative compounds, their preparation methods, and uses. This invention synthesizes a novel polyADP-ribose polymerase (PARP) inhibitor derivative, the structure of which includes: a first structural unit with the clinical PARP inhibitor olaparib as the core backbone, a linker arm L, and a quinoline carboxylic acid fragment R; wherein the structural types and substituents of the linker arm L and the quinoline carboxylic acid fragment R are adjustable. This invention also provides a method for preparing the compound, which is characterized by simple steps, strong versatility, and ease of structural expansion, suitable for constructing compound libraries with different combinations of linker arms and different quinoline carboxylic acid fragments. The compound can be used to prepare drugs or drug compositions for inhibiting tumor cell proliferation and treating tumor-related diseases, showing excellent application prospects.

The application provides a double-stranded walking type DNA nanomachine and a preparation method and application thereof, and relates to the technical field of fluorescent analysis and detection.The double-stranded walking type DNA nanomachine for ctDNA fluorescent detection comprises a gold nanoparticle carrier, an anchor probe, a FAM fluorescent reporter probe, a double-stranded walking arm, a Cas12a protein and a crRNA to form a ribonucleoprotein complex.The walking arm of a conventional CRISPR / Cas12a nanomachine is a DNA single-stranded structure, which is easily cut in trans by activated Cas12a, thereby reducing the stability and sensitivity of the nanomachine.The application introduces a double-stranded DNA structure into the walking arm design to replace the conventional DNA single-stranded walking arm, constructs a double-stranded walking type three-dimensional DNA CRISPR / Cas12a nanomachine, effectively resists the reverse cutting of Cas12a on the walking arm, maintains the structural integrity and functional stability of the nanomachine, and greatly improves the detection sensitivity and specificity of lung cancer ctDNA, thereby having a good clinical application prospect.

The invention discloses a multi-system function regeneration factor composition as well as a preparation method and application thereof. The multi-system function regeneration factor composition is prepared from the following components in parts by mass: 0.8 to 2.4 parts of melatonin, 84 to 126 parts of nicotinamide ribose and 42 to 84 parts of resveratrol. According to the multi-system functional regeneration factor composition disclosed by the invention, through scientific proportioning and synergistic effect of melatonin, nicotinamide ribose and resveratrol, the functions of stem cells are strongly activated, proliferation of the stem cells is remarkably promoted, the stemness maintaining capability of the stem cells is improved, osteogenesis and adipogenesis differentiation potential is enhanced, and the regeneration effect of the stem cells is improved. Meanwhile, an NAD < + > metabolic pathway is activated so as to strengthen cell energy and anti-aging capability. The capsule adopts the design of combining quick-release pellets and sustained-release pellets, the quick-release part can quickly release melatonin, the local drug concentration can be increased in a short time, and stem cell activation signals can be quickly started; and the sustained release part slowly releases nicotinamide ribose and resveratrol to maintain the long-acting stability of the drug concentration, so that the effect taking speed is ensured, the action time is prolonged, and the bioavailability is greatly improved.

Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2′-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

The present application relates to ticagrelor intermediates and a preparation method thereof, wherein a halogenated group of compound VI is removed by a deacidifying agent to open a ring, process conditions are simple, and operation is easy; meanwhile, a chiral center in a molecule is constructed by using a transaminase to prepare compound VII from compound VI, conditions are more mild, chiral selectivity is better, raw material utilization is improved, chiral separation or chiral reduction process is avoided, and industrialized production is more beneficial. The disclosed technical scheme can be connected with a process for preparing compound VII from D-ribose as a starting material, forming a process for preparing target compound ticagrelor intermediate compound VII from compound I (D-ribose) as a raw material, synthesizing compound II by reacting with methanol, then synthesizing compound III by sulfonylization of compound II, then synthesizing compound IV by halogen substitution of compound III, and further opening a ring, closing a ring, and catalyzing by a transaminase.

The invention belongs to the technical field of formula foods for special medical purposes, and particularly relates to a fat component for treating Alzheimer's disease and a preparation method of the fat component. The fat component is prepared from the following raw materials in parts by weight: medium-chain triglyceride, starch sugar, silicon dioxide, sodium caseinate, starch sodium octenylsuccinate, mono-glycerol fatty acid ester, diglycerol fatty acid ester and potassium hydroxide. And a neuroprotective nutrient combination. According to the invention, the medium-chain triglyceride capable of supplying energy quickly is creatively combined with the nerve protection nutrient with a specific mechanism. The medium-chain triglyceride provides efficient ketone energy; magnesium citrate stabilizes the excitability of neurons; the nicotinamide ribose supports cell energy metabolism; the omega-3 fatty acid plays roles in resisting inflammation and repairing nerve cell membranes. The four components provide protection from energy supply, neuron stabilization, metabolism support and structure repair, and bring better neurological function prognosis while controlling the Alzheimer's disease.

This invention relates to lipid nanoparticles for in vivo skin gene editing in fish and their applications, belonging to the field of fish gene editing technology. The lipid nanoparticles for in vivo skin gene editing in fish comprise: a gene editing element and a lipid layer, wherein the lipid layer coats the surface of the gene editing element; the gene editing element is a CRISPR / Cas9 ribonucleoprotein complex or a nucleic acid encoding the complex; the lipid nanoparticle carrier comprises ionizable cationic lipids, auxiliary lipids, cholesterol, polyethylene glycol-modified lipids, and permanently cationic lipids, and by molar weight, the proportions are 15 parts ionizable cationic lipids, 25-30 parts auxiliary lipids, 30 parts cholesterol, 3 parts polyethylene glycol-modified lipids, and 7 parts permanently cationic lipids. The formulation of this invention is highly targeted, has high editing efficiency, is simple and safe to operate, and has broad application prospects.

The present disclosure relates to a novel system for the generation and use of hybrid alpha-pseudoviruses against ribose viruses. A hybrid ribose virus-alpha-pseudovirus (HRAP) presents a novel particle having an RNA genome derived from an alphavirus and a structural protein of a virus in the ribose virus field. The HRAP particle is formed by assembling structural proteins crossing different riboviridae and can be used for vaccine development, antiviral drug screening, neutralization test, treatment or immune response starting and the like.

A method for treating a homologous recombination (HR)-deficient cancer, a homologous recombination (HR)-proficient cancer or a cancer that is resistant to DNA repair and DNA damage response (DDR) inhibitor therapy, such as Poly (ADP-Ribose) Polymerase (PARP) inhibitor therapy, is provided, the method comprising administering to a subject an RNA-binding motif protein 39 (RBM39) degrader, such as an aryl sulfonamide. A DDR inhibitor, such as a PARP inhibitor, may also be administered. A composition comprising a RBM39 degrader, such as an aryl sulfonamide, e.g., E7820 or Compound A, and a DDR inhibitor, such as a PARP inhibitor, is also provided.

The application discloses a method for detecting glutathione by using manganese-based chiral nanomaterials, and belongs to the field of chemical engineering, specifically to the field of analytical chemistry technology. The method comprises the following steps: taking a dispersion liquid of manganese-based chiral nanomaterials as a detection reagent, mixing the detection reagent with a sample containing glutathione to be detected, and comparing a circular dichroism spectrum signal with a standard curve to obtain the concentration of the sample containing glutathione to be detected; wherein a chiral ligand of the manganese-based chiral nanomaterials is ribose. Based on the circular dichroism spectrum detection, the detection wavelength band used is in the visible light region, is not easy to be disturbed, is sensitive, and the resolution can reach 3 muM, and the detection limit is 1.5 muM, which has important significance and value for promoting the development of the fields of optics, life science, medicine and the like.

The present invention relates to compounds and compositions containing said compounds acting as PARP inhibitors (Poly (ADP-ribose) polymerase). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.

This invention relates to the field of biomedical technology, specifically to a serum-free and protein-free culture medium and its preparation method for enhancing NK cell expansion and cytotoxic activity. The serum-free and protein-free culture medium comprises a basal medium, an AMPK-HIF1α regulator, immunomodulatory factors, mitochondrial function enhancers, antioxidants, trace elements, and a pH buffer. The AMPK-HIF1α regulator is composed of α-ketoglutarate at a final concentration of 1.4-1.6 mmol / L and AICAR at 0.4-0.6 mmol / L. This culture medium activates the AMPK-HIF1α pathway through precise formulation of α-ketoglutarate and AICAR, and optimizes the metabolic-antioxidant network in synergy with nicotinamide ribose and glutathione, thus solving the industry problem of the incompatibility between expansion and function in serum-free NK cell culture.

The present application belongs to the technical field of medicine, and particularly relates to a poly (ADP ribose) polymerase (PARP) selective inhibitor compound, a pharmaceutically acceptable salt or a stereoisomer thereof, a pharmaceutical composition containing the compound, the pharmaceutically acceptable salt or the stereoisomer thereof, a method for preparing the compound, the pharmaceutically acceptable salt or the stereoisomer thereof, and the use of the compound, the pharmaceutically acceptable salt or the stereoisomer thereof.

A comprehensive teaching aid system for genetic science at least including numerous (deoxy-) ribonucleotide models that can be assembled to form DNA / RNA single strands, or to form the beautiful DNA double helix structure when numerous adjacently and oppositely connected deoxynucleotide models are attached by magnets, tRNAs, and three different plates for DNA replication, mRNA transcription and protein synthesis respectively. The (deoxy-) nucleotide model includes a phosphate model, a (deoxy-) ribose model and a base model connected in sequence. Between two adjacently disposed (deoxy-) ribonucleotide models, a (deoxy-) ribose model is connected to a phosphate model in the head-to-tail fashion to form a detachable and flexible chain structure. The base model is laterally connected to the (deoxy-) ribose model, and two base models in two oppositely disposed deoxynucleotide models are flexibly and complementarily attached.

The application discloses a PACE structure modified cap analog, which is based on the existing cap analog structure, has ribose bases or modified ribose bases at both ends, three ribose structures in the middle and a triphosphonate segment or a phosphonate segment connecting the ribose structures, and has one or more PACE structures or PACE derivative structures on the triphosphonate segment or the phosphonate segment, namely, (alkoxy)alkyl-COOH or a salt thereof with or without substitution on the triphosphonate or the phosphonate, so that the IVT yield and capping efficiency are improved, and the translation efficiency of the target mRNA is improved.

The present application relates to the technical field of organic synthesis, and particularly relates to a preparation method of beta-nicotinamide mononucleotide. The present application provides a preparation method of beta-nicotinamide mononucleotide, comprising the following steps: mixing a salt corresponding to nicotinamide riboside, phosphorus oxychloride and a polar aprotic organic solvent, performing a phosphorylation reaction, and obtaining beta-nicotinamide mononucleotide. The present application takes nicotinamide riboside as a raw material, takes phosphorus oxychloride as a phosphorylation reagent, and is prepared through a phosphorylation reaction. Compared with a conventional method, the reaction has less by-products and is simple to operate. The subsequent high-purity and high-yield end product can be obtained through simple post-treatment. Meanwhile, the present application is also beneficial to industrial production.

The invention discloses an ergothioneine composition for improving ovarian vitality and a preparation method and application thereof, the composition comprises D-ribose and ergothioneine, the concentration of the D-ribose in the composition is 5-15 mM, and the concentration of the ergothioneine in the composition is 100-300 [mu] M. The pharmaceutical composition is used for regulating the redox balance of ovarian granular cells, inhibiting inflammatory response and up-regulating anti-mullerian hormone secretion so as to improve the ovarian activity.

The present invention relates to a tricyclic compound of formula (I) and its analogue useful for the treatment of breast and ovarian cancer. In particular, the present invention relates to novel tricyclic compound as PARP1 / 2 inhibitor, designed to block the activity of the enzyme Poly (ADP-ribose) polymerase (PARP1 / 2), which plays a crucial role in DNA damage repair, particularly in cancer cells. The synthesized inhibitor molecules having improved solubility, bioavailability and no haematological toxicity can be useful in potential cancer therapies, and defects in DNA repair pathways.

The application provides a muscle building and shaping, fat control composition, a preparation method, application and product, and relates to the field of food technology.The composition according to the application is composed of the following raw materials in parts by weight: 30-100 parts of branched chain amino acid, 1-2 parts of casein hydrolysate, 10-50 parts of collagen peptide powder, 0.4-2 parts of cinnamon powder, 0.5-2 parts of purple tea concentrated powder, 5-10 parts of black pepper extract, 1-2 parts of concentrated freeze-dried watermelon powder and 2-8 parts of d-ribose; wherein the black pepper and ethanol solution are mixed, and the black pepper extract is obtained by means of extraction under the condition of heating and auxiliary microwave treatment. In the composition according to the application, the components interact with each other, and the muscle building, shaping and fat control effects are synergistically improved. The composition according to the application is applied to products with the effects of muscle building, shaping and fat control, and the effects are remarkable.

The invention relates to an anti-aging composition, and belongs to the field of medicines and health-care product preparations. The composition is a microcapsule assembled by a water-soluble wall material, a first core material, a fat-soluble wall material and a second core material which are sequentially coated from outside to inside, and the first core material comprises beta-nicotinamide mononucleotide (NMN), nicotinamide ribose (NR), ergothioneine and trimethylglycine (TMG); the second core material comprises resveratrol, curcumin, pyrroloquinoline quinone (PQQ) and spermidine, and is dissolved in medium chain triglyceride (MCT oil) containing an antioxidant tocopherol. According to the dosage form, physical isolation and differentiated release of water-soluble and fat-soluble components are realized, and the problems of incompatibility among the components, poor stability, low bioavailability and the like are solved. Through the multi-target synergistic effect, the composition can effectively improve the NAD + level and enhance the mitochondrial function so as to improve the skin state and delay senescence.

The utility model discloses integrated D-ribose ultrafiltration membrane equipment which comprises a mounting rack, two groups of vertically arranged filter cartridges are fixedly mounted in the mounting rack, one group of filter cartridges consists of more than one individual, a vertically arranged support plate is fixedly connected to the bottom of the mounting rack, and the support plate is fixedly connected to the bottom of the mounting rack. A second water inlet pipe and a second water outlet pipe are rotationally connected into the supporting plate, the same water inlet pipe set is fixedly inserted into the ends of the two filter cartridges, the same water outlet pipe set is fixedly inserted into the outer portions of the two filter cartridges, and the second water inlet pipe and the two water inlet pipe sets as well as the second water outlet pipe and the two water outlet pipe sets are each provided with a reversing assembly. According to the utility model, the reversing assembly is arranged, so that another group of filtering pieces can be quickly replaced, the seamless continuous work of the device can be ensured, and any adverse effect of module replacement on the working efficiency can be effectively prevented.

The present invention relates to a stable pharmaceutical composition comprising a phthalazinone derivative having excellent activity as a poly(ADP-ribose) polymerase inhibitor.

This disclosure relates to lipid compounds and lipid nanoparticles (LNPs) prepared therefrom that are particularly effective in delivery of circular polyribonucleotides. Methods of use of the lipid compounds and LNPs, e.g., for circular RNA delivery, are also provided.